Pierre Caloz took over as Site Head Bern in December 2016. Since then the manufacturing site in Wankdorf has seen positive development, most recently with the expansion project Protinus. With this major investment of more than 250 Mio. Swiss Francs CSL Behring in Bern is among the biggest global manufacturers of immunoglobulins. The site and its over 1700 employees are strongly positioned for the future and continue to gain momentum.
Pierre Caloz changes within the organization to the position of Head of Manufacturing for the regions Europe & Asia Pacific with immediate effect. In this function, he is responsible for the manufacturing sites in Bern, Lengnau BE, Marburg (GER), Melbourne (AUS) and Wuhan (CHN). With his proven expertise in the biotech industry he will support the development of a global strategy that aligns CSL Behring’s manufacturing needs to support growth and ensure that we can meet current and future demand for our therapies. Pierre Caloz continues to be based in Bern
His successor in Bern and new Senior Vice President & General Manager is Martin Schären. Martin Schären joined the company in 1999. In his 20 years with CSL, Martin Schären has held numerous manufacturing and site leadership roles, including Director, Quality Control and Quality Assurance, Vice President Manufacturing & Supply Chain at Bern, and Senior Vice President & General Manager at Broadmeadows. Most recently, he has served as Senior Vice President, Supply Chain Transformation. From 2008 to 2015, he was Senior Director, Manufacturing at the Bern site and deputy to the Site Head. In 2015, he moved to Australia on a long-term assignment as Senior Vice President & General Manager of the site in Melbourne. After his return to Switzerland, he now takes over as Site Head of the Bern manufacturing site.
Martin Schären holds a Bachelor in Chemistry of the University of Applied Sciences of Burgdorf, Switzerland. He lives with his wife in Herrenschwanden near Bern.
The appointment of Martin Schären has major significance for CSL Behring AG and the manufacturing site in Bern. It emphasizes the importance and continuity that CSL gives to immunoglobulins, its strongest product range. The site in Wankdorf looks ahead with confidence. Martin Schären, born and raised in Bern, is an acknowledged expert in the manufacturing of pharmaceutical/biopharmaceutical products. He has extensive leadership experience and knows the industry and its interfaces well.
With both persons based in Bern, the transition phase will happen throughout October and allows it to be as smooth as possible.
